SARS-CoV-2 Serology Did Not Predict Risk of Breakthrough Infection During the Omicron BA.1 and BA.2 Surge
Arch Pathol Lab Med
.
2024 Jan 1;148(1):7-11.
doi: 10.5858/arpa.2023-0311-LE.
Authors
Katia J Bruxvoort
1
2
,
Jiaxiao Shi
2
,
Hubert Song
2
,
Komal Narwaney
3
,
Jason M Glanz
3
,
Ingrid Binswanger
3
4
5
,
Jessica A Lam
6
,
John M Chang
2
,
Cecilia Portugal
2
,
Cheryl Watanabe
7
,
Michael Aragones
2
,
Darryl E Palmer-Toy
7
Affiliations
1
Department of Epidemiology, University of Alabama at Birmingham.
2
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.
3
Institute for Health Research, Kaiser Permanente Colorado, Aurora; Department of Epidemiology, Colorado School of Public Health, Aurora.
4
Chemical Dependency Treatment Services, Colorado Permanente Medical Group, Aurora.
5
Bernard J. Tyson School of Medicine, Pasadena, California (Binswanger).
6
Department of Clinical Analysis, Southern California Permanente Medical Group, Pasadena.
7
Regional Reference Laboratories, Southern California Permanente Medical Group, Chino Hills.
PMID:
37796481
DOI:
10.5858/arpa.2023-0311-LE
No abstract available
MeSH terms
Breakthrough Infections*
COVID-19*
Humans
SARS-CoV-2